Our History

Arcinova's Alnwick, UK site has a legacy dating back to the 1980s, when it was owned by one of the world's largest pharmaceutical companies. It later became part of a leading global CRO, specialising in discovery and early-stage development services. In 2016 the site transitioned into an independent company and was established as Arcinova.

In early 2021, Quotient Sciences acquired Arcinova, bringing together Arcinova's expertise in drug substance development, ¹⁴C radiolabelling and bioanalytical testing with Quotient Sciences' integrated development and clinical manufacturing capabilities.

Throughout 2022 and 2023, Quotient Sciences invested in and expanded its Alnwick, UK facility, adding new equipment and increasing capacity to support Annex 1-compliant sterile fill-finish operations for parenteral drug products.

In 2025, Quotient Sciences announced the strategic reintroduction of Arcinova, A Quotient Sciences Company. 

Based in Alnwick, UK, Arcinova integrates drug substance and drug product expertise, providing seamless support from development through to clinical supply.